StocksMedium•16 November 2026•
1 min read
ALX Oncology Q3 Losses Wider Than Analyst Estimates
Key Facts
1ALX Oncology reported a GAAP EPS of -$0.15, missing analyst estimates by $0.02.
ALX Oncology reported a GAAP loss per share of $0.15 for the third quarter of 2026, missing analyst estimates by $0.02. According to Seeking Alpha, the company's periodic financial results revealed a performance miss relative to Wall Street consensus expectations for the quarter.
Cash, cash equivalents, and investments for ALX Oncology totaled $147.2 million as of September 30, 2026, with the company stating these funds are sufficient to support operations through the first half of 2028. The stock ALXO closed at $1.04 on November 13, 2026, after reaching a day high of $1.12 and a low of $0.9361.